ONTTF (Oxford Nanopore Technologies) Total Current Assets : $657.5 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Oxford Nanopore Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Oxford Nanopore Technologies's total current assets for the quarter that ended in Dec. 2024 was $657.5 Mil.

Oxford Nanopore Technologies Total Current Assets Historical Data

The historical data trend for Oxford Nanopore Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Nanopore Technologies Total Current Assets Chart

Oxford Nanopore Technologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

273.06

998.15

777.10

566.05

657.52

Oxford Nanopore Technologies Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial							777.10	688.10	566.05	562.01	657.52

Oxford Nanopore Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Oxford Nanopore Technologies's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	427.775	+	56.338	+	125.731	+	47.672
	=	657.5

Oxford Nanopore Technologies's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	427.775	+	56.338	+	125.731	+	47.672
	=	657.5

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Oxford Nanopore Technologies (OTCPK:ONTTF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Oxford Nanopore Technologies's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	427.775	-	196.855	+	0.75 * 47.099	+	0.5 * 125.731
=	329.1

Oxford Nanopore Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Oxford Nanopore Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Nanopore Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Nanopore Technologies PLC (OTCPK:ONTTF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ONTl:UK ONT:UK 4R0:Germany

Address

Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, GBR, OX4 4DQ

Website

https://www.nanoporetech.com

Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing.